SCHEMBL7303796

SCHEMBL7303796

CCCc1nc(C(C)(C)O)c(C(=O)OCC)n1Cc1ccc(-c2ccccc2C(=O)NC(C)(C)C)cc1

nearest known ligand 0.82

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 3/20 0.56
AGTR2 P50052 2/20 0.56
ABCC3 O15438 1/20 0.55
ABCC4 O15439 1/20 0.55
ABCB11 O95342 1/20 0.55
CYP3A4 P08684 1/20 0.55
PDE4D Q08499 1/20 0.55
PDE3A Q14432 1/20 0.55
SLCO1B3 Q9NPD5 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SLCO1B1 Q9Y6L6 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7310143 0.91 AGTR1 (0.63) AGTR1AGTR2
SCHEMBL7309439 0.90 PPARG (0.60) AGTR1AGTR2ABCC3ABCC4ABCB11
Hydrochloric Acid SCHEMBL7303166 0.90 AGTR1 (0.62) AGTR1AGTR2
SCHEMBL7310636 0.90 AGTR1 (0.66) AGTR1AGTR2
SCHEMBL8562435 0.89 AGTR1 (0.55) AGTR1AGTR2ABCC3ABCC4ABCB11
SCHEMBL7309505 0.89 AGTR1 (0.57) AGTR1AGTR2ABCC3ABCC4ABCB11
SCHEMBL8562433 0.89 AGTR1 (0.57) AGTR1AGTR2ABCC3ABCC4ABCB11
Hydrochloric Acid SCHEMBL8568424 0.88 AGTR1 (0.58) AGTR1AGTR2ABCC3ABCC4ABCB11
SCHEMBL8560944 0.87 AGTR1 (0.55) AGTR1AGTR2ABCC3ABCC4ABCB11
SCHEMBL7432496 0.85 AGTR1 (0.61) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298763-B1 METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-03-25 EP disclosed
US-8735598-B2 Method for producing 1-biphenylmethylimidazole compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
US-8735598-B2 Method for producing 1-biphenylmethylimidazole compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
US-20110092713-A1 METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-21 US disclosed
US-20110092713-A1 METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-21 US disclosed
EP-2298763-A1 METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND Daiichi Sankyo Company, Limited (JP) 2011-03-23 EP disclosed
EP-0503785-B1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-04-25 EP disclosed
US-5646171-A HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 1997-07-08 US disclosed
US-5616599-A HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER SANKYO COMPANY, LIMITED (JP) 1997-04-01 US disclosed
EP-0503785-A1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use Sankyo Company Limited (JP) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092713-A1 METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND AGTR1, AGTR2, AOC3 AGTR1 1/4885AGTR2 2/4885ABCC3 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.